Catalyst
Slingshot members are tracking this event:
Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABEO | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Abo-102, Aav- Sgsh, Mucopolysaccharidosis Type Iiia, Mps Iiii A
